HS-10504

DRUG5 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced or Metastatic NSCLCHealthy ParticipantsLocally Advanced or Metastatic NSCLCLung Cancer

Phase 1

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

RecruitingNCT06461156

Jiangsu Hansoh Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC

Start: 2024-06-26End: 2027-03-31Target: 230Updated: 2026-08-31

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruitingNCT07414953

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lung Cancer

Start: 2026-03-30End: 2028-11-30Target: 400Updated: 2026-02-17

A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504

Not yet recruitingNCT07764692

Jiangsu Hansoh Pharmaceutical Co., Ltd.Healthy Participants

Start: 2026-08-01End: 2027-03-31Target: 8Updated: 2026-08-14

A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504

Not yet recruitingNCT07770217

Jiangsu Hansoh Pharmaceutical Co., Ltd.Healthy Participants

Start: 2026-08-02End: 2026-11-29Target: 18Updated: 2026-08-18

Phase 3

Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

Not yet recruitingNCT07754123

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced or Metastatic NSCLC

Start: 2026-09-17End: 2031-07-31Target: 206Updated: 2026-08-10

Related Papers

Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study

Cancer Research2026-04-17